Updating results

3562 results

Sort: Relevance | Date

Axumin for functional imaging of prostate cancer recurrence (MIB172)

Advice on the use of Axumin for functional imaging of prostate cancer recurrence to aid local decision making

Medtech innovation briefing Published February 2019

Prevena incision management system for closed surgical incisions (MIB173)

Advice on the use of Prevena incision management system for closed surgical incisions to aid local decision making

Medtech innovation briefing Published February 2019

The OPTIMIZER smart system for managing heart failure (MIB186)

Advice on the use of the OPTIMIZER smart system for managing heart failure to aid local decision making

Medtech innovation briefing Published June 2019

HemaClear for bloodless surgical field during limb surgery (MIB187)

Advice on the use of HemaClear for bloodless surgical field during limb surgery to aid local decision making

Medtech innovation briefing Published July 2019

Endo-SPONGE for colorectal anastomotic leakage (MIB188)

Advice on the use of Endo-SPONGE for colorectal anastomotic leakage to aid local decision making

Medtech innovation briefing Published August 2019

The V.A.C. Veraflo Therapy system for infected wounds (MIB189)

Advice on the use of the V.A.C. Veraflo Therapy system for infected wounds to aid local decision making

Medtech innovation briefing Published September 2019

Servo-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children (MIB163)

Advice on the use of Serve-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children to aid local decision-making

Medtech innovation briefing Published October 2018

Axonics sacral neuromodulation system for overactive bladder and faecal incontinence (MIB164)

Advice on the use of Axonics sacral neuromodulation system (SNM) for overactive bladder and faecal incontinence to aid local decision-making

Medtech innovation briefing Published December 2018

Cerebrotech Visor for detecting stroke (MIB165)

Advice on the use of Cerebrotech Visor for detecting stroke to aid local decision-making

Medtech innovation briefing Published December 2018

CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MIB174)

Advice on the use of CADScor system for ruling out coronary artery disease in people with stable coronary artery disease symptoms to aid local decision-making

Medtech innovation briefing Published March 2019

IQoro for stroke-related dysphagia (MIB175)

Advice on the use of IQoro for stroke-related dysphagia to aid local decision making

Medtech innovation briefing Published March 2019

IQoro for hiatus hernia (MIB176)

Advice on the use of IQoro for hiatus hernia to aid local decision making

Medtech innovation briefing Published March 2019

AlignRT in breast cancer radiotherapy (MIB157)

Advice on the use of AlignRT (Vision RT) in breast cancer radiotherapy to aid local decision-making

Medtech innovation briefing Published August 2018

Rezum for treating benign prostatic hyperplasia (MIB158)

Advice on the use of Rezum (NxThera Inc) for treating benign prostatic hyperplasia (BPH) to aid local decision-making

Medtech innovation briefing Published August 2018

Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide (KTT24)

This document summarises the evidence base on suicide prevention: optimising medicines and reducing access to medicines as a means of suicide . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published March 2019 Last updated September 2019

Lipid-modifying drugs (KTT3)

This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on lipid-modifying drugs. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Asthma: medicines safety priorities (KTT5)

This document summarises the evidence base on asthma: medicines safety priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Hypnotics (KTT6)

This document summarises the evidence base on hypnotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Antipsychotics in people living with dementia (KTT7)

This document summarises the evidence base on antipsychotics in people living with dementia . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

First-choice antidepressant use in adults with depression or generalised anxiety disorder (KTT8)

The key therapeutic topic first-choice antidepressant use in adults with depression or generalised anxiety disorder has been retired from the 2017 update of medicines optimisation: key therapeutic topics. The version published in 2016 is available here for information but it has not been updated since February 2016. Like all the other key therapeutic topics it is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated February 2016

Safer insulin prescribing (KTT20)

This document summarises the evidence base on safer insulin prescribing . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2017 Last updated September 2019

Medicines optimisation in chronic pain (KTT21)

This document summarises the evidence base on medicines optimisation in chronic pain . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2017 Last updated September 2019

Chemotherapy dose standardisation (KTT22)

This document summarises the evidence base on chemotherapy dose standardisation . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published February 2018 Last updated September 2019

Shared decision making (KTT23)

This document summarises the evidence base on shared decision making . It is a key therapeutic topic that has been identified to support Medicines Optimisation. It is not formal NICE guidance .

Key therapeutic topic Published March 2019 Last updated September 2019

Wound care products (KTT14)

This document summarises the evidence base on wound care products . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Biosimilar medicines (KTT15)

The key therapeutic topic biosimilar medicines has been retired from the 2019 update of medicines optimisation: key therapeutic topics. The version published in 2018 is available here for information but it has not been updated since February 2018. Like all the other key therapeutic topics it is not formal NICE guidance .

Key therapeutic topic Published February 2016 Last updated February 2018

Anticoagulants, including direct-acting oral anticoagulants (DOACs) (KTT16)

This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on anticoagulants , including direct-acting oral anticoagulants (DOACs). It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published February 2016 Last updated September 2019

Type 2 diabetes mellitus: medicines optimisation priorities (KTT12)

This document summarises the evidence base on type 2 diabetes mellitus: medicines optimisation priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Laxatives (KTT1)

The key therapeutic topic laxatives has been retired from the 2016 update of medicines optimisation: key therapeutic topics. The version published in 2015 is available here for information but it has not been updated since January 2015. Like all the other key therapeutic topics it is not formal NICE guidance .

Key therapeutic topic Published January 2015

Non-steroidal anti-inflammatory drugs (KTT13)

The key therapeutic topic non-steroidal anti-inflammatory drugs has been retired from the 2019 update of medicines optimisation: key therapeutic topics. The version published in 2018 is available here for information but it has not been updated since February 2018. Like all the other key therapeutic topics it is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated February 2018

Minocycline (KTT11)

The key therapeutic topic minocycline has been retired from the 2016 update of medicines optimisation: key therapeutic topics. The version published in 2015 is available here for information but it has not been updated since January 2015. Like all the other key therapeutic topics it is not formal NICE guidance .

Key therapeutic topic Published January 2015

Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI (KTT17)

This document summarises the evidence base on the use of medicines in people with or at increased risk of acute kidney injury . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published February 2016 Last updated September 2019

Multimorbidity and polypharmacy (KTT18)

This document summarises the evidence base on multimorbidity and polypharmacy . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2017 Last updated September 2019

Psychotropic medicines in people with learning disabilities whose behaviour challenges (KTT19)

This document summarises the evidence base on psychotropic medicines in people with learning disabilities whose behaviour challenges . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2017 Last updated September 2019

Renin-angiotensin system drugs: dual therapy (KTT2)

The key therapeutic topic renin-angiotensin system drugs: dual therapy has been retired from the 2017 update of medicines optimisation: key therapeutic topics. The version published in 2016 is available here for information but it has not been updated since February 2016. Like all the other key therapeutic topics it is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated February 2016

Antimicrobial stewardship: prescribing antibiotics (KTT9)

This document summarises the evidence base on antimicrobial stewardship: prescribing antibiotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

Key therapeutic topic Published January 2015 Last updated September 2019

Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

Evidence summary Published December 2015

Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)

Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making

Evidence summary Published December 2015

External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment (ESNM66)

Summary of the evidence on green tea (Camellia sinensis) leaf extract 10% ointment for treating external genital and perianal warts to inform local NHS planning

Evidence summary Published December 2015

Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)

Summary of the evidence on oxycodone/naloxone prolonged release for treating restless leg syndrome (RLS) to inform local NHS planning and decision-making

Evidence summary Published December 2015

Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM62)

Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 1 diabetes mellitus to inform local NHS planning and decision-making

Evidence summary Published October 2015

Coronary revascularisation: Cangrelor (ESNM63)

Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making

Evidence summary Published November 2015

Glaucoma: brinzolamide/brimonidine combination eye drops (ESNM56)

Summary of the evidence on brinzolamide/brimonidine combination eye drops for treating glaucoma to inform local NHS planning and decision-making

Evidence summary Published March 2015

Chronic obstructive pulmonary disease: aclidinium/formoterol (ESNM57)

Summary of the evidence on aclidinium/formoterol for chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published April 2015

Ulcerative colitis: budesonide multimatrix (Cortiment) (ESNM58)

Summary of the evidence on budesonide multimatrix (Cortiment) for treating ulcerative colitis (UC) to inform local NHS planning and decision-making

Evidence summary Published June 2015

Type 2 diabetes: dulaglutide (ESNM59)

Summary of the evidence on dulaglutide for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published June 2015

Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)

Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published July 2015

Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)

Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making

Evidence summary Published October 2015

Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream (ESNM68)

Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making

Evidence summary Published January 2016

Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)

Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making

Evidence summary Published March 2016